What was checked
Immunotherapy 2.0 therapies (NK cells, CAR-NK, cancer vaccines, tumor DNA monitoring, camelid antibodies) are now here today to maintain long-term cancer-free status, prevent recurrence in millions of patients, and win the war on cancer
Assessment summary
Needs cautionCAR-NK therapies remain primarily investigational, while the cited review identifies NK-92 as authorized for clinical trials rather than as an approved treatment. FDA's approved cellular and gene therapy list does not establish CAR-NK as a routine approved therapy. Personalized cancer vaccines are being studied in active clinical trials, including trials for patients with molecular residual disease. Early immune responses and relapse-free follow-up do not establish broad, proven recurrence prevention.